



Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy

Guest Editors:

Dr. Manish Tripathi

1. Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA

2. South Texas Center of Excellence in Cancer Research, University of Texas Rio Grande Valley, McAllen, TX 78504, USA

Dr. Puneet Vij

1. Department of Pharmaceutical Sciences, St. John's University, Queens, NY 11432, USA

2. Michigan Public Health Institute, Okemos, MI 48842, USA

Message from the Guest Editors

This Special Issue, “Two Decades of Progress in the Prevention and Treatment of Colorectal Cancer: From Aspirin to Targeted Therapy”, aims to provide a comprehensive overview of the advancements made in the field of colorectal cancer prevention and treatment over the past two decades. This Special Issue intends to gather cutting-edge research, review articles, and expert opinions that highlight the significant milestones, breakthroughs, and emerging trends in the management of colorectal cancer.

Deadline for manuscript submissions:

31 August 2024





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)